35 results on '"Xie, L"'
Search Results
2. Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication
3. The role of chemoradiotherapy in organ preservation for rectal cancer
4. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
5. 1507P Distinct enomic features between osteosarcomas initially metastasing to bone and to lung
6. Cruciferous vegetables consumption and the risk of female lung cancer: a prospective study and a meta-analysis
7. LBA60 Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
8. 1567P Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
9. 514MO The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
10. Meat consumption and risk of lung cancer: evidence from observational studies
11. 143P Novel anti-PD-L1 antibody TQB2450 (T) in combination with anlotinib (A) in patients with advanced soft tissue sarcoma (STS), the results from the expanded sample size and updated data
12. 1320TiP The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study
13. 102P Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
14. 1788P Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial
15. 1646P Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study
16. 664P Efficacy of triptorelin after radical prostatectomy in patients with high-risk prostate cancer
17. 1644P Dynamic changes in quality of life and Q-TWiST analysis for Ewing sarcoma patients following anlotinib and irinotecan: A combination of phase Ib and II trial
18. Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
19. A China-manufactured bevacizumab biosimilar, HLX04, matches bevacizumab sourced from China, USA and the European Union
20. 877P Genetic testing and results in Chinese gynecological tumour patients
21. 101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
22. 286P Efficacy, safety and pharmacokinetics (PK) of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC): An Asian multinational study
23. Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study
24. PSA-PFS in metastatic or high risk prostate cancer patients treated with GnRH antagonist (degarelix) versus LHRH agonists – A pooled analysis of data from the Americas, Europe and Asia
25. 105P - A China-manufactured bevacizumab biosimilar, HLX04, matches bevacizumab sourced from China, USA and the European Union
26. 239O RECORD-4: Multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis
27. Bioinformatics Analyses of Genome-Wide Expression Profile and Copy Number Variations (Cnvs) of Small Cell Esophageal Cancer (Scec)
28. Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)
29. 286P Efficacy, safety and pharmacokinetics (PK) of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naive patients (pts) with progressive metastatic castration-resistantprostate cancer(mCRPC):AnAsianmultinationalstudy
30. 749P - Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study
31. 735P - PSA-PFS in metastatic or high risk prostate cancer patients treated with GnRH antagonist (degarelix) versus LHRH agonists – A pooled analysis of data from the Americas, Europe and Asia
32. 1157P - Bioinformatics Analyses of Genome-Wide Expression Profile and Copy Number Variations (Cnvs) of Small Cell Esophageal Cancer (Scec)
33. 456P - Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)
34. P37-1 A diagnostic nomogram for pathological invasiveness in early LUAD: integration of autoantibody and radiomics features.
35. MO57-3 Effect of immunochemotherapy time-of-day infusion, sequence and interval on prognosis of advanced esophageal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.